Therapy Areas: Oncology
Inhibrx's INBRX-109 receives EMA orphan medicinal product designation to treat chondrosarcoma
16 August 2022 -

Inhibrx, Inc. (Nasdaq: INBX), a US-based biotechnology company with four clinical programs in development, announced on Monday that the European Medicines Agency (EMA) has granted orphan medicinal product designation for INBRX-109 to treat chondrosarcoma, an orphan bone cancer with approximately 2,800 new patients diagnosed annually in the United States and the EU.

The company received approval for the product based on a positive opinion issued by the EMA. Orphan drug designation in the EU can provide certain benefits, including reduced regulatory fees, clinical protocol assistance and the potential for up to ten years of market exclusivity following regulatory approval.

The product, a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody, is aimed at exploiting the tumour-biased cell death induced by DR5 activation.